SEC Form 4 · accession 0001104659-18-017864
Amphastar Pharmaceuticals, Inc. · AMPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason B. Shandell
Officer — President and General Counsel · Director
Period of report
Mar 13, 2018
Accepted (ET)
Mar 15, 2018 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001297184
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 13, 2018 | M | 300 | $11.79 | A | 217,248 | D | |
| Common Stock | Mar 13, 2018 | S | 300 | $20.45 | D | 216,948 | D | |
| Common Stock | Mar 14, 2018 | M | 400 | $11.79 | A | 217,348 | D | |
| Common Stock | Mar 14, 2018 | S | 400 | $20.45 | D | 216,948 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $11.79 | Mar 13, 2018 | M | 300 | D | — | Sep 28, 2020 | Common Stock | 300 | 5,700 | D |
| Employee Stock Option (right to buy)F2 | $11.79 | Mar 14, 2018 | M | 400 | D | — | Sep 28, 2020 | Common Stock | 400 | 5,300 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2017.
- F2Shares subject to the option are fully vested and immediately exercisable.
Remarks
Exhibit 24 - Power of Attorney